In this sense, burosumab is an anti-FGF23 fully human monoclonal antibody that has shown to improve many of the XLH complications in children [14, 15, 33, 34] and adults [35–38] increasing their quality of life. Here, FGF23 is linked to X-linked hypophosphatemia.